Your session is about to expire
← Back to Search
Stem Cell Therapy
Intravitreal autologous CD34+ cells for Retinitis Pigmentosa (BMSCRP1 Trial)
Phase 1
Waitlist Available
Led By Susanna Park, MD PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Summary
This trial will test whether it is safe to give participants with retinitis pigmentosa an injection of their own stem cells in order to improve their vision.
Eligible Conditions
- Retinitis Pigmentosa
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility of intravitreal injection of autologous CD34+ cells
Safety of intravitreal injection of autologous CD34+ cells
Secondary study objectives
Best corrected visual acuity
Electroretinography
Microperimetry
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Intravitreal autologous CD34+ cellsExperimental Treatment1 Intervention
Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions
Find a Location
Who is running the clinical trial?
University of California, DavisLead Sponsor
928 Previous Clinical Trials
4,721,014 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
453 Patients Enrolled for Retinitis Pigmentosa
Cures Within ReachOTHER
22 Previous Clinical Trials
2,089 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
12 Patients Enrolled for Retinitis Pigmentosa
Retina SocietyUNKNOWN
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger